CSL Commits $1.5 Billion to Illinois Plant, Doubling Down on U.S. Biomanufacturing Hub
This analysis is based on a report originally published by Manufacturing Dive.
KANKAKEE, Ill. — In a significant bet on the growing market for specialized biologic medicines, CSL Limited has launched a $1.5 billion expansion of its CSL Behring manufacturing plant here. The project underscores the Australia-based company's deepening investment in the United States, where it has funneled over $3 billion into operations since 2018.
The expansion will specifically boost output of CSL's leading immunoglobulin therapies, Privigen and Hizentra, which are critical for patients with immune deficiencies and neurological disorders. A key feature will be the implementation of CSL's proprietary "Horizon 2" manufacturing process, designed to extract significantly more therapeutic protein from a given amount of donated plasma.
"This isn't just about adding square footage; it's about strategic capacity in a supply-constrained market," said Gordon Naylor, CSL's CEO and Managing Director. "As demand for these life-sustaining therapies climbs globally, Kankakee becomes an even more vital node in our network."
The company stated that the more than 1,200 existing employees at the site will be retained, with the potential for hundreds of new jobs created during and after construction. This follows a pattern of U.S. job growth for CSL, which now employs nearly 19,000 people across the country.
Background & Market Context: Plasma-derived therapies are essential for treating a range of rare, chronic, and acute conditions—from hemophilia to trauma care. The global market is projected to grow steadily, driven by increased diagnosis and an aging population. CSL's investment signals a move to secure production capacity ahead of this demand curve, particularly in the U.S., which is both a major plasma donor base and a key consumer market.
Voices from the Community:
- Dr. Anya Sharma, Immunologist at Great Lakes Medical Center: "For my patients with primary immunodeficiencies, consistent access to immunoglobulin is non-negotiable. This expansion is a welcome commitment to supply stability. The advanced Horizon 2 process could also be a game-changer in efficiency, potentially benefiting the entire supply chain."
- Michael Torres, Economic Development Director, Kankakee County: "This is transformative for our community. CSL isn't just a major employer; they're a high-skill anchor that attracts supporting industries and talent. It validates our region as a bona fide biomanufacturing corridor."
- Rebecca Vance, Patient Advocate & Founder of 'Rare Voice': "Let's not just applaud the corporate press release. A $1.5B expansion is massive, and I have to ask: will this actually improve affordability and access for patients? Or will it just bolster profit margins? We need guarantees that this scaling up translates to fewer shortages and more equitable pricing, not just shareholder value."
- Carl Jenkins, Retired Union Foreman: "Good jobs staying in Illinois—that's what I see. In an era of offshoring, a company doubling down here with union labor for construction and high-paying permanent jobs is a win. It keeps our kids employed right at home."